阿托伐他汀对急性冠脉综合征患者血清妊娠相关蛋白-A及C反应蛋白的影响

目的:探讨阿托伐他汀对急性冠脉综合征(ACS)患者血清妊娠相关蛋白-A(PAPP-A)和C反应蛋白(CRP)的影响。方法:选取ACS患者(ACS组)105例和正常对照组90例,测定其PAPP-A及CRP水平,将105例ACS患者随机分阿托伐他汀20mg组(高剂量组,51例)和阿托伐他汀10mg组(低剂量组,54例),分别采用20mg和10mg阿托伐他汀治疗1周后,再次测定PAPP-A及CRP水平。结果:ACS组血清PAPP-A和CRP水平高于对照组,差异有统计学意义(P<0.01)。治疗前,高剂量组和低剂量组的PAPP-A及CRP水平差异无统计学意义,治疗后高剂量组和低剂量组的PAPP-A及CRP水平均低于治疗前,治疗后高剂量组的PAPP-A及CRP水平均低于低剂量组,差异均有统计学意义(P<0.01)。结论:阿托伐他汀可以减轻ACS患者的炎症反应,稳定冠脉粥样硬化斑块。

Effects of Atorvastatin on Serum Concentration of PAPP-A and C-Reactive Protein in Patients with Acute Coronary Syndrome

Objective: To investigate effects of atorvastatin on the serum concentration of pregnancy-associated plasma protein (PAPP)-A and C-reactive protein (CRP) in patients with acute coronary syndrome (ACS). Methods: The serum concentrations of PAPP-A and CRP were measured before and after one week treatment with atorvastatin (20 mg and 10 mg) in 105 ACS patients and 90 control subjects. Results: There were significantly higher serum levels of PAPP-A and CRP in patients with ACS than those of control subjects (P < 0.01). There were no significant differences in serum levels of PAPP-A and CRP before treatment with atorvastatin between 10 mg group and 20 mg group. After treatment with atorvastatin there were lower serum levels in PAPP-A and CRP in these two groups. The serum levels of PAPP-A and CRP were significantly lower in patients with 20 mg atorvastatin treatment than those of patients with 10 mg treatment (P < 0.01). Conclusion: Atorvastatin?can reduce the?inflammation?in patients with ACS,?and stable?coronary atherosclerotic plaque.